Current Report Filing (8-k)
March 19 2020 - 6:06AM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of
The
Securities Exchange Act of 1934
Date
of Report (Date of Earliest Event Reported): March 19, 2020
Commission
File No. 000-16929
Soligenix,
Inc.
(Exact
name of small business issuer as specified in its charter)
DELAWARE
|
|
41-1505029
|
(State
or other jurisdiction of incorporation or organization)
|
|
(I.R.S.
Employer Identification Number)
|
|
|
|
29
Emmons Drive,
Suite
B-10
Princeton,
NJ
|
|
08540
|
(Address
of principal executive offices)
|
|
(Zip
Code)
|
(609)
538-8200
|
(Issuer’s
telephone number, including area code)
|
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant
under any of the following provisions (see General Instruction A.2. below):
☐
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities
registered pursuant to Section 12(b) of the Act:
Title
of each class
|
|
Trading
Symbol(s)
|
|
Name
of each exchange on which registered
|
Common
Stock, par value $.001 per share
|
|
SNGX
|
|
The
Nasdaq Capital Market
|
Common
Stock Purchase Warrants
|
|
SNGXW
|
|
The
Nasdaq Capital Market
|
Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405
of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging
growth company ☐
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for
complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
☐
Item
8.01. Other Events.
On
March 19, 2020, Soligenix, Inc. issued a press release announcing positive preliminary top-line results for its pivotal Phase
3 FLASH (Fluorescent Light Activated Synthetic Hypericin) trial evaluating SGX301 (Synthetic Hypericin) in the treatment of cutaneous
T-cell lymphoma. The full text of the press release is filed as Exhibit 99.1 to this Current Report on Form 8-K and incorporated
herein by reference.
Item 9.01. Financial
Statements and Exhibits.
(d) Exhibits.
SIGNATURE
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf
by the undersigned hereunto duly authorized.
|
Soligenix,
Inc.
|
March
19, 2020
|
By:
|
/s/
Christopher J. Schaber
|
|
|
Christopher
J. Schaber, Ph.D.
President
and Chief Executive Officer
(Principal
Executive Officer)
|
2
Soligenix (NASDAQ:SNGX)
Historical Stock Chart
From Aug 2024 to Sep 2024
Soligenix (NASDAQ:SNGX)
Historical Stock Chart
From Sep 2023 to Sep 2024